RxDoctor Payments DataLook up a doctor →

Gregory Brunin, MD

Ophthalmology · San Antonio, TXNPI 1043579733

Payments from drug & device makers

$708,871in general payments, 2019–2025

Across 125 payments — averaging $5670.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$567K
  • AbbVie$74K
  • Bausch Health US, LLC$32K
  • Rxsight Inc$23K
  • Bausch & Lomb Americas Inc.$9K
  • Glaukos Corporation$4K
  • plus $1K from 17 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$2K

What the payments were for

  • Consulting fees$432%
  • Food & beverage$2,47698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$708,871 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$633,535
Medicare patients
1,774
Services billed
5,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine66$71,392
XiidraLifitegrast32$58,316
Cyclosporine41$33,526
Prednisolone Acetate777$25,766
LumiganBimatoprost29$17,800
Fluorometholone133$12,800
MoxifloxacinMoxifloxacin Hcl529$10,739
Latanoprost663$9,117
Ketorolac Tromethamine430$6,761
CombiganBrimonidine Tartrate/Timolol12$4,779
RhopressaNetarsudil Mesylate14$4,371
Travoprost20$4,114
Timolol Maleate79$3,618
TobradexTobramycin/Dexamethasone12$3,089
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat162$2,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$74,172$93,972107 claims
Bausch & Lomb Americas Inc.Xiidra$8,630$58,31632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →